TY - JOUR
T1 - European consensus proposal for immunoglobulin therapies
AU - Sewell, W. A.Carrock
AU - Kerr, Jacqueline
AU - Behr-Gross, Marie Emmanuelle
AU - Peter, Hans Hartmut
AU - Behr-Gross, Marie Emmanuelle
AU - Drabwell, Jose
AU - Eibl, Martha
AU - Golding, Basil
AU - Kuijpers, Taco
AU - Quinti, Isabella
AU - van Schaik, Ivo N.
AU - Sediva, Anna
AU - Seppänen, Mikko
AU - Späth, Peter J.
PY - 2014/8
Y1 - 2014/8
N2 - The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for replacement and immunomodulation therapy worldwide has tripled in the past 20 years and represents an ever-increasing cost factor for healthcare organizations. The limited access to the starting material of this essential medicinal product is currently the driving force for human plasma collection. Increasing awareness and improved diagnosis of human primary immunodeficiencies and a broadening of immunomodulatory indications are responsible for this development, and on a longer run might lead to plasma supply shortages. Consensus recommendations for the optimal use of Ig in clinical practice, including priority rankings for the most urgent indications, are therefore urgently needed. During a recent meeting in Kreuth, Germany, expert nominees from 36 Council of Europe states, together with colleagues from observer countries and regulatory agencies came up with this consensus statement.
AB - The use of immunoglobulin (Ig) preparations (intravenous, IVIg, subcutaneous, SCIg) for replacement and immunomodulation therapy worldwide has tripled in the past 20 years and represents an ever-increasing cost factor for healthcare organizations. The limited access to the starting material of this essential medicinal product is currently the driving force for human plasma collection. Increasing awareness and improved diagnosis of human primary immunodeficiencies and a broadening of immunomodulatory indications are responsible for this development, and on a longer run might lead to plasma supply shortages. Consensus recommendations for the optimal use of Ig in clinical practice, including priority rankings for the most urgent indications, are therefore urgently needed. During a recent meeting in Kreuth, Germany, expert nominees from 36 Council of Europe states, together with colleagues from observer countries and regulatory agencies came up with this consensus statement.
KW - Antibodies
KW - Immunodeficiencies
KW - Immunoglobulins
KW - Immunopathology
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84906087039&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/eji.201444700
DO - https://doi.org/10.1002/eji.201444700
M3 - Article
C2 - 24975475
SN - 0014-2980
VL - 44
SP - 2207
EP - 2214
JO - European journal of immunology
JF - European journal of immunology
IS - 8
ER -